Extrovis and Dr. Reddy’s (RDY) Laboratories announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac 0.5%, in the US market, approved by the U.S. Food and Drug Administration. Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s Fluorouracil Cream, 0.5%, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDY:
- Dr. Reddy’s Laboratories to Engage in Virtual Investor Conference on August 21, 2025
- Dr. Reddy’s Laboratories Receives Positive USFDA Inspection Outcome
- Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval
- Dr. Reddy’s Laboratories Concludes 41st AGM with Key Resolutions
- Dr. Reddy’s Laboratories Releases Q1 2025 Financial Results